TY - JOUR
T1 - Prevalence of coeliac disease in patients with rheumatoid arthritis and juvenile idiopathic arthritis
T2 - a systematic review and meta-analysis
AU - Forss, Anders
AU - Sotoodeh, Adonis
AU - van Vollenhoven, Ronald F.
AU - Ludvigsson, Jonas F.
N1 - Publisher Copyright: © Copyright CliniCal and ExpErimEntal rhEumatology 2024.
PY - 2024/3/1
Y1 - 2024/3/1
N2 - Objective The reported prevalence of coeliac disease (CD) in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) varies in previous studies. We aimed to examine the prevalence of CD in patients with RA and JIA. Methods We searched Medline, Embase, Cochrane and Web of Science Core Collection between 1 January 1990 and 31 October 2022. In our primary analysis, the prevalence of biopsy-confirmed CD in RA and JIA patients was investigated. In secondary analyses, the prevalence of serological markers for CD was examined. Pooled weighted prevalences of CD and serological markers with 95% confidence intervals (95%CI) were calculated and quality of included studies was assessed. Meta-regression analysis was performed on publication year, sample size, CD prevalence in the general population, proportion of females, and quality assessment score. Results In this systematic review, 14 publications were deemed relevant for RA and 22 for JIA, with nine and 18 included in the primary analyses of CD prevalence, respectively. Among a total of 754 RA patients and 2077 patients with JIA, the weighted pooled prevalence estimates of biopsy-confirmed CD were 0.4% (95%CI=0.0–1.2) and 1.4% (95%CI= 0.7–2.2), respectively. The pooled prevalence estimates of positive CD serology were 0.9% (95%CI=0.3–1.9) in RA and 5.4% (95%CI=2.5–9.2) in JIA. Conclusion In this meta-analysis, we found a pooled prevalence of biopsy-confirmed CD in patients with RA and JIA comparable to that in the general population. Routine screening for CD is not warranted in RA but could be considered in JIA patients with additional risk factors for CD.
AB - Objective The reported prevalence of coeliac disease (CD) in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) varies in previous studies. We aimed to examine the prevalence of CD in patients with RA and JIA. Methods We searched Medline, Embase, Cochrane and Web of Science Core Collection between 1 January 1990 and 31 October 2022. In our primary analysis, the prevalence of biopsy-confirmed CD in RA and JIA patients was investigated. In secondary analyses, the prevalence of serological markers for CD was examined. Pooled weighted prevalences of CD and serological markers with 95% confidence intervals (95%CI) were calculated and quality of included studies was assessed. Meta-regression analysis was performed on publication year, sample size, CD prevalence in the general population, proportion of females, and quality assessment score. Results In this systematic review, 14 publications were deemed relevant for RA and 22 for JIA, with nine and 18 included in the primary analyses of CD prevalence, respectively. Among a total of 754 RA patients and 2077 patients with JIA, the weighted pooled prevalence estimates of biopsy-confirmed CD were 0.4% (95%CI=0.0–1.2) and 1.4% (95%CI= 0.7–2.2), respectively. The pooled prevalence estimates of positive CD serology were 0.9% (95%CI=0.3–1.9) in RA and 5.4% (95%CI=2.5–9.2) in JIA. Conclusion In this meta-analysis, we found a pooled prevalence of biopsy-confirmed CD in patients with RA and JIA comparable to that in the general population. Routine screening for CD is not warranted in RA but could be considered in JIA patients with additional risk factors for CD.
KW - coeliac disease
KW - juvenile idiopathic arthritis
KW - prevalence
KW - rheumatoid arthritis
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85189375976&partnerID=8YFLogxK
U2 - 10.55563/clinexprheumatol/b92b8a
DO - 10.55563/clinexprheumatol/b92b8a
M3 - Article
C2 - 37933564
SN - 0392-856X
VL - 44
SP - 608
EP - 618
JO - Clinical and experimental rheumatology
JF - Clinical and experimental rheumatology
IS - 3
ER -